BriaCell Therapeutics Announces Proposed Public Offering of Common Shares
PHILADELPHIA and VANCOUVER, British Columbia, Feb. 03, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care,
BriaCell Therapeutics (NASDAQ:BCTX – Get Free Report) had its price target lifted by investment analysts at HC Wainwright from $15.00 to $32.00 in a research note issued to investors on ...
Shares of BriaCell Therapeutics Corp. (NASDAQ:BCTX) climbed 10% following the announcement of a significant clinical response ...
Detailed price information for Briacell Therapeutics Corp (BCT-T) from The Globe and Mail including charting and trades.
Investing.com -- BriaCell Therapeutics Corp. (NASDAQ: BCTX ...
Lung metastasis (from metastatic breast cancer) resolved - after only 2 months (4 doses) of treatment with Bria-OTS ...
Therapeutics trading halted, volatility trading pauseMaximize Your Portfolio with Data Driven Insights:Leverage the ...
费城和不列颠哥伦比亚省温哥华讯 - 专注于癌症免疫疗法的临床阶段生物技术公司BriaCell Therapeutics Corp.今日宣布计划进行普通股的尽力公开发售。该公司目前市值为250万美元，EBITDA为-422万美元，正积极寻求加强其财务状况。此次发售的完成和具体条款将取决于市场条件，目前尚无法确定发售是否能够完成及其具体细节。
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback